Pancreatic cancer

#KRAS #Pancreatic cancer

McCormick wins Stephenson Global Prize for ‘innovative’ research 

The inaugural Stephenson Global Prize has been awarded to Dr Frank McCormick for his groundbreaking discoveries into pancreatic cancer.  The Stephenson Global Prize, presented for the first time in Boston, Massachusetts, was established to reward visionary researchers with resources to accelerate discoveries that could change the trajectory… Read More

#News

Pancreatic cancer
#Autophagy #Cancer Research UK #KRAS #Oncology #Pancreatic cancer

Autophagy disruption provides clues to cancer development

Scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer.   The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.   The research was… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer vaccine #Colorectal cancer #Gene mutation #Oncology #Pancreatic cancer #UCLA

Off-the-shelf cancer vaccine shows promise in KRAS-driven cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer.  The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cancer
#Cancer research #Pancreatic cancer #Tumours

Benzaldehyde halts the growth of pancreatic cancer

Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer. By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #iOnctura #Pancreatic cancer #Tumours

Breaking barriers in pancreatic cancer

World Pancreatic Cancer Day takes place on 21 November to raise awareness about pancreatic cancer, support patients and their families, and advocate for increased research and early detection of this deadly disease. iOnctura’s Chief Medical Officer Michael Lahn discusses how we can fight the disease by breaking the defensive wall surrounding… Read More

#Cancer Research #Exclusive Content

Pancreatic cancer
#Oncology #Panavance Therapeutics #Pancreatic cancer #Phase I trial

Interim data reveals potential of new pancreatic cancer drug

Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More

#Cancer Research #News

Pancreatic cancer
#Chemotherapy-resistance #Oncology #Pancreatic cancer #Stanford University #Treatment resistance

Study reveals potential target for new pancreatic cancer treatments

Researchers at Stanford University have revealed new insights related to pancreatic cancer’s resistance to chemotherapy. In a new paper, the scientists revealed that its resistance is related to both the physical stiffness of the tissue around the cancerous cells and the chemical makeup… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cancer
#FDA #Fibrosis #iOnctura #Oncology #Orphan drugs #Pancreatic cancer

Orphan Drug Designation for first-in-class autotaxin cancer therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring… Read More

#Cancer Research #News #Regulatory

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News

Pancreatic cancer
#Amplia Therapeutics #Australia #Cancer research #Oncology #Pancreatic cancer #Phase II trial

Phase IIa trial launches in advanced pancreatic cancer

The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients. In November 2023, Amplia Therapeutics announced completion of the Phase Ib stage of the ACCENT trial where ascending… Read More

#Cancer Research #News

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #The Institute of Cancer Research #University of Michigan

Uridine discovery could lead to new pancreatic cancer therapies

Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #Propanc Biopharma #Solid tumours #Spain #Tumour microenvironment (TME)

Proenzyme suppresses TGF-β pathway in pancreatic cancer

A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. Read More

#Cancer Research #Editor's Choice #News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

This week in drug discovery (20-24 March)

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More

#News